Short chain fatty acids (SCFAs) improves TNBS-induced colitis in zebrafish

The short-chain fatty acids (SCFAs) are metabolites originated from the fermentation of dietary fibers and amino acids produced by the bacteria of the intestinal microbiota. The most abundant SCFAs, acetate, propionate, and butyrate, have been proposed as a treatment for inflammatory bowel diseases...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current research in immunology 2021, Vol.2, p.142-154
Hauptverfasser: Morales Fénero, Camila, Amaral, Mariana Abrantes, Xavier, Izabella Karina, Padovani, Barbara Nunes, Paredes, Lais Cavalieri, Takiishi, Tatiana, Lopes-Ferreira, Mônica, Lima, Carla, Colombo, Alicia, Saraiva Câmara, Niels Olsen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The short-chain fatty acids (SCFAs) are metabolites originated from the fermentation of dietary fibers and amino acids produced by the bacteria of the intestinal microbiota. The most abundant SCFAs, acetate, propionate, and butyrate, have been proposed as a treatment for inflammatory bowel diseases (IBDs) due to their anti-inflammatory properties. This work aimed to analyze the effects of the treatment of three combined SCFAs in TNBS-induced intestinal inflammation in zebrafish larvae. Here, we demonstrated that SCFAs significantly increased the survival of TNBS-exposed larvae, preserved the intestinal endocytic function, reduced the expression of inflammatory cytokines and the intestinal recruitment of neutrophils caused by TNBS. However, SCFAs treatment did not appear to avoid TNBS-induced tissue damage in the intestinal wall and did not restore the number of mucus-producing goblet cells. Finally, exposure to TNBS induced dysbiosis of the microbiota with an increase in Betaproteobacteria and Actinobacteria, while the treatment with SCFAs maintained these population levels similar to control. Thus, we demonstrate that the treatment of three combined SCFAs presented anti-inflammatory properties previously seen in mammals, opening an opportunity to use zebrafish to explore the potential benefit of these and other metabolites to treat inflammation. [Display omitted] •Short-chain fatty acids reduce intestinal inflammation in larval zebrafish.•Survival is increased but intestinal tissue damage is not restored.•Microbiota dysbiosis caused by intestinal inflammation is similar to mammals.•Short-chain fatty acids are capable to regulate dysbiosis.•Zebrafish is an excellent model to study the effect of microbiota metabolites.
ISSN:2590-2555
2590-2555
DOI:10.1016/j.crimmu.2021.08.003